N.M.K. holds a Wyeth/Canadian Institute for Health Research Chair in Transplantation Research and is a Senior Scholar of the Alberta Heritage Foundation for Medical Research.
Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application†
Article first published online: 25 MAY 2006
Copyright © 2006 American Association for the Study of Liver Diseases
Volume 43, Issue 6, pages 1346–1353, June 2006
How to Cite
Kneteman, N. M., Weiner, A. J., O'Connell, J., Collett, M., Gao, T., Aukerman, L., Kovelsky, R., Ni, Z.-J., Hashash, A., Kline, J., Hsi, B., Schiller, D., Douglas, D., Tyrrell, D. L. J. and Mercer, D. F. (2006), Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology, 43: 1346–1353. doi: 10.1002/hep.21209
Potential conflict of interest: Dr. Tyrrell is an officer and shareholder in Virexx. Dr. Mercer owns stock in KMT Hepatech.
- Issue published online: 25 MAY 2006
- Article first published online: 25 MAY 2006
- Manuscript Accepted: 22 MAR 2006
- Manuscript Received: 1 JUN 2005
- KMT Hepatech, Inc.
- Chiron, Inc.
- 14Viropharma, Inc. Press Release, (www.viropharma.com) July 15, 2003.